Zetia and Nexavar drive Bayer's pharma growth in Japan
This article was originally published in Scrip
Bayer's sales of prescription drugs in Japan grew by just over 9% to ¥171.5 billion ($1.83 billion) at reimbursement prices in calendar 2009, with the increase being driven mainly by high cholesterol product Zetia (ezetimibe) and Nexavar (sorafenib) for cancer.
You may also be interested in...
Corporate consolidation and specialization were major threads running through the 2010s in Japan. Reimbursement pricing issues continued to dominate the policy sphere while new forms of therapy benefited from positive regulatory reforms.
BeiGene licenses antibody therapeutics for Castleman’s disease and high-risk neuroblastoma.
BeiGene’s license agreement with Leap Therapeutics covers Asia, except for Japan, along with Australia and New Zealand. Apollomics obtains rights in China and beyond to GlycoMimetics’ e-selectin antagonists.